ACTA2

Across TCGA pan-cancer cohorts, ACTA2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACTA2 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ACTA2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACTA2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

OV, ESCA, and BLCA are the cancer types where ACTA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.168	0.541	.005	18	view →
ESCA	DFS	Median	All	0.045	0.533	<.001	12	view →
BLCA	DFS	Median	All	0.210	0.520	.046	6	view →
SKCM	DFS	Median	III,IV	1.000	0.492	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACTA2–OV (DFS)

Open the OV breakdown →